GILD

65.33

0.27% -0.18

Dopo l'orario di chiusura: 65.09 -0.24 -0.37%

Gilead Sciences, Inc. (GILD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GILD Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$65.51

Aprire:

$65.75

Volume 24 ore:

5.45M

Capitalizzazione di mercato:

$81.46B

Reddito:

$27.45B

Utile/perdita netta:

$484.00M

Rapporto P/E:

15.02

EPS:

4.35

Flusso di cassa netto:

$8.48B

1 W Prestazione:

+0.09%

1M Prestazione:

-9.38%

6M Prestazione:

-19.57%

1 anno Prestazione:

-18.78%

Intervallo 1D:

$64.89

$65.80

Portata 52W:

$64.63

$87.86

Gilead Sciences, Inc. Stock (GILD) Company Profile

Nome

Gilead Sciences, Inc.

Settore

Healthcare (1190)

Industria

Drug Manufacturers - General (18)

Telefono

650-574-3000

Indirizzo

333 Lakeside Drive, Foster City, CA

Dipendente

10,000

Cinguettio

@GileadSciences

Prossima data di guadagno

2024-05-15

Ultimi documenti SEC

GILD's Discussions on Twitter

Gilead Sciences, Inc. Stock (GILD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-09-08	Aggiornamento	BofA Securities	Neutral → Buy
2023-09-06	Iniziato	HSBC Securities	Reduce
2023-07-24	Reiterato	Barclays	Equal Weight
2023-05-16	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Ripresa	Piper Sandler	Overweight
2023-01-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Ripresa	BofA Securities	Neutral
2022-12-09	Downgrade	DZ Bank	Buy → Hold
2022-10-31	Aggiornamento	Barclays	Underweight → Equal Weight
2022-10-28	Reiterato	BMO Capital Markets	Market Perform
2022-10-28	Reiterato	Cowen	Outperform
2022-10-28	Reiterato	JP Morgan	Overweight
2022-10-28	Reiterato	Jefferies	Buy
2022-10-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-28	Reiterato	RBC Capital Mkts	Outperform
2022-10-28	Aggiornamento	Truist	Hold → Buy
2022-10-28	Reiterato	Wells Fargo	Equal Weight
2022-10-04	Aggiornamento	JP Morgan	Neutral → Overweight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-05-23	Iniziato	SVB Leerink	Mkt Perform
2022-02-28	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Reiterato	BMO Capital Markets	Outperform
2022-02-02	Reiterato	BofA Securities	Neutral
2022-02-02	Reiterato	RBC Capital Mkts	Outperform
2022-02-02	Reiterato	Truist	Hold
2022-02-02	Reiterato	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Argus	Hold → Buy
2022-01-06	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Ripresa	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Neutral
2021-11-19	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Ripresa	Piper Sandler	Neutral
2021-10-20	Ripresa	Cowen	Outperform
2021-07-30	Reiterato	BMO Capital Markets	Market Perform
2021-07-30	Reiterato	RBC Capital Mkts	Outperform
2021-04-01	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-03-30	Aggiornamento	Redburn	Neutral → Buy
2021-01-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2020-11-03	Ripresa	Morgan Stanley	Equal-Weight
2020-10-28	Iniziato	UBS	Neutral
2020-09-30	Ripresa	Jefferies	Buy
2020-09-15	Aggiornamento	Maxim Group	Hold → Buy
2020-07-31	Reiterato	Credit Suisse	Neutral
2020-07-31	Reiterato	Morgan Stanley	Equal-Weight
2020-07-31	Reiterato	Piper Sandler	Overweight
2020-07-31	Reiterato	RBC Capital Mkts	Outperform
2020-07-31	Reiterato	SunTrust	Hold
2020-07-31	Reiterato	Wells Fargo	Equal Weight
2020-07-20	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-06-03	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Aggiornamento	SunTrust	Sell → Hold
2020-05-01	Downgrade	JP Morgan	Overweight → Neutral
2020-05-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-01	Downgrade	SunTrust	Hold → Sell
2020-04-27	Downgrade	UBS	Buy → Neutral
2020-04-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-17	Downgrade	CFRA	Hold → Sell

Mostra tutto

Gilead Sciences, Inc. Borsa (GILD) Ultime notizie

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Zacks Investment Research

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Gilead Sciences, Inc. Azioni (GILD) Dati Finanziari

Gilead Sciences, Inc. (GILD) Reddito 2024

GILD ha riportato un ricavo (TTM) di $27.45 miliardi per il trimestre terminato il 2024-03-31, un +1.50% salita anno su anno.

Gilead Sciences, Inc. (GILD) Reddito netto 2024

GILD l'utile netto (TTM) è stato di $484.00 milioni per il trimestre terminato il 2024-03-31, un -91.33% diminuire anno su anno.

Gilead Sciences, Inc. (GILD) Flusso di cassa 2024

GILD ha registrato un flusso di cassa disponibile (TTM) di $8.48 miliardi per il trimestre conclusosi con 2024-03-31, un +1.13% aumento anno su anno.

Gilead Sciences, Inc. (GILD) Utile per azione 2024

L'utile per azione (TTM) di GILD è stato pari a $0.36 per il trimestre terminato il 2024-03-31, un -91.87% declino anno su anno.

Gilead Sciences, Inc. Azioni (GILD) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003
Parsey Merdad	Chief Medical Officer	Sep 12 '23	Sale	76.99	1,501	115,562	70,130